Aqualung Therapeutics Corp.
2 clinical trials · Sponsor
◉ Watch Aqualung Therapeutics Corp.
| Record | Firm | Date |
|---|---|---|
| Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS (NCT05938036) | Aqualung Therapeutics Corp. | 2023-12-01 |
| First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100 (NCT05426746) | Aqualung Therapeutics Corp. | 2022-07-05 |
Track Aqualung Therapeutics Corp. automatically
Every clearance here is in the API, with alerts when new ones post.